The main types of chronic obstructive pulmonary disease (COPD) are emphysema and chronic bronchitis. They differ in the kind of damage they do to the airways and lungs. However, the causes, symptoms, and treatment of the two conditions are almost completely identical.
There are four stages of COPD that range from mild to very severe. A person with mild COPD may not know that they have the condition, while someone with very severe COPD will experience life threatening symptoms.
Keep reading to learn about the types and stages of COPD, including causes, symptoms, and treatment options.
What is COPD?
Phynart Studio/Getty Images
Press release content from PR Newswire. The AP news staff was not involved in its creation.
New Treatment for Severe Emphysema Now Covered Under Highmark Blue Cross Blue Shield
January 18, 2021 GMT
The FDA-Approved Olympus Spiration® Valve System Is a Breakthrough Device Used for the Therapeutic Treatment of Severe Emphysema, a Form of COPD.
The FDA-Approved Olympus Spiration® Valve System Is a Breakthrough Device Used for the Therapeutic Treatment of Severe Emphysema, a Form of COPD.
CENTER VALLEY, Pa., Jan. 18, 2021 /PRNewswire/ Olympus announced that Highmark Blue Cross Blue Shield (BCBS) updated its coverage policy to include the Spiration® Valve System for eligible patients suffering from severe emphysema, a form of Chronic Obstructive Pulmonary Disease (COPD). This coverage provides a minimally invasive treatment alternative for eligible patients.
Lung diseases rise, but pulmonary function tests ignored - The Sunday Guardian Live sundayguardianlive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from sundayguardianlive.com Daily Mail and Mail on Sunday newspapers.
Almirall, S.A. (ALM.MC) and Forest Laboratories, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved Tudorza(TM) Pressair(TM) (aclidinium bromide inhalation powder) for the long-term maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. COPD is a common, progressive, and debilitating lung disease characterized by persistent airflow limitation that makes it hard to breathe; it is currently the third leading cause of mortality in the US. Characteristic symptoms include breathlessness, excessive production of sputum, and a chronic cough. Tudorza(TM) is a twice-daily inhaled long-acting anticholinergic, also referred to as a long-acting muscarinic antagonist (LAMA). Tudorza(TM) produces bronchodilation by inhibiting acetylcholine s effect on muscarinic receptors in the airway smooth muscle. Forest expects Tudorza(TM) Pressair(TM) to be available to wholesalers in the
18 December, 2020
This article, the first in a two-part series on pulmonary administration of medicines, summarises the use of inhaled therapies and describes the procedure for teaching patients to use pressurised metered dose inhalers with and without a spacer
Abstract
Inhaled medications are the mainstay of pharmacological treatment for people with chronic obstructive pulmonary disease and asthma. Correct inhaler technique and appropriate delivery devices are essential for optimal treatment. This first article in a two-part series provides an introduction to using inhaled therapies and describes the procedure for teaching patients to use pressurised metered-dose inhalers with and without a spacer. Part 2 will describe the procedure for the use of dry-powder inhalers and nebulisers for medicines administration.